• Published On : Nov-2017 |
  • Pages : 170 Pages |
  • Format :

Table of Content

Chapter 1 Global Outlook
1.1 Pharmaceutical Industry: Global Outlook

Chapter 2 Global Immune Checkpoint Inhibitors Market - Executive Summary

Chapter 3 Global Immune Checkpoint Inhibitors Market Overview
3.1 Introduction
    3.1.1 Global Immune Checkpoint Inhibitors Market Taxonomy
    3.1.2 Global Immune Checkpoint Inhibitors Market Definition
3.2 Global Immune Checkpoint Inhibitors Market Size (US$ Mn) and Forecast, 2012-2026
    3.2.1 Global Immune Checkpoint Inhibitors Market Y-o-Y Growth
3.3 Global Immune Checkpoint Inhibitors Market Dynamics
3.4 Supply Chain
3.5 PESTLE Analysis
3.6 Regionwise Market Positioning Assessment
3.7 Porter’s Five Forces Analysis
3.8 Pipeline Assessment
    3.8.1 AstraZeneca Plc.
    3.8.2 Bristol-Myers Squib
    3.8.3 Celldex Therapeutics Inc.
    3.8.4 Roche Holdings AG
    3.8.5 Merck & Co., Inc.
    3.8.6 Merck KgaA & Pfizer Inc.
    3.8.7 Sanofi
3.9 Reimbursement Support Scenario
    3.9.1 OPDIVO® (nivolumab) & YERVOY® (ipilimumab)
    3.9.2 Tecentriq
    3.9.3 KEYTRUDA (pembrolizumab)
3.10 Key Participants Market Presence (Intensity Map) By Region

Chapter 4 Global Immune Checkpoint Inhibitors Market Analysis and Forecast 2012-2026
4.1 Global Immune Checkpoint Inhibitors Market Size and Forecast by Drug Class, 2012-2026
    4.1.1 PD-1 Market Size and Forecast, 2012-2026
          4.1.1.1 Revenue (US$ Mn) Comparison, By Region
          4.1.1.2 Market Share Comparison, By Region
          4.1.1.3 Y-o-Y growth Comparison, By Region
    4.1.2 PD-L1 Market Size and Forecast, 2012-2026
          4.1.2.1 Revenue (US$ Mn) Comparison, By Region
          4.1.2.2 Market Share Comparison, By Region
          4.1.2.3 Y-o-Y growth Comparison, By Region
    4.1.3 CTLA-4 Market Size and Forecast, 2012-2026
          4.1.3.1 Revenue (US$ Mn) Comparison, By Region
          4.1.3.2 Market Share Comparison, By Region
          4.1.3.3 Y-o-Y growth Comparison, By Region
4.2 Global Immune Checkpoint Inhibitors Market Size and Forecast by Distribution Channel, 2012-2026
    4.2.1 Hospital Pharmacies Market Size and Forecast, 2012-2026
          4.2.1.1 Revenue (US$ Mn) Comparison, By Region
          4.2.1.2 Market Share Comparison, By Region
          4.2.1.3 Y-o-Y growth Comparison, By Region
    4.2.2 Retail Pharmacies Market Size and Forecast, 2012-2026
          4.2.2.1 Revenue (US$ Mn) Comparison, By Region
          4.2.2.2 Market Share Comparison, By Region
          4.2.2.3 Y-o-Y growth Comparison, By Region
    4.2.3 Specialty Pharmacies Market Size and Forecast, 2012-2026
          4.2.3.1 Revenue (US$ Mn) Comparison, By Region
          4.2.3.2 Market Share Comparison, By Region
          4.2.3.3 Y-o-Y growth Comparison, By Region
4.3 Global Immune Checkpoint Inhibitors Market Size and Forecast by Therapeutic Application, 2012-2026
    4.3.1 Melanoma Market Size and Forecast, 2012-2026
          4.3.1.1 Revenue (US$ Mn) Comparison, By Region
          4.3.1.2 Market Share Comparison, By Region
          4.3.1.3 Y-o-Y growth Comparison, By Region
    4.3.2 Lung Cancer Market Size and Forecast, 2012-2026
          4.3.2.1 Revenue (US$ Mn) Comparison, By Region
          4.3.2.2 Market Share Comparison, By Region
          4.3.2.3 Y-o-Y growth Comparison, By Region
    4.3.3 Blood Cancers Market Size and Forecast, 2012-2026
          4.3.3.1 Revenue (US$ Mn) Comparison, By Region
          4.3.3.2 Market Share Comparison, By Region
          4.3.3.3 Y-o-Y growth Comparison, By Region
    4.3.4 Renal Cell Carcinoma Market Size and Forecast, 2012-2026
          4.3.4.1 Revenue (US$ Mn) Comparison, By Region
          4.3.4.2 Market Share Comparison, By Region
          4.3.4.3 Y-o-Y growth Comparison, By Region
    4.3.5 Squamous Cell Carcinoma Market Size and Forecast, 2012-2026
          4.3.5.1 Revenue (US$ Mn) Comparison, By Region
          4.3.5.2 Market Share Comparison, By Region
          4.3.5.3 Y-o-Y growth Comparison, By Region
    4.3.6 Urothelial Carcinoma Market Size and Forecast, 2012-2026
          4.3.6.1 Revenue (US$ Mn) Comparison, By Region
          4.3.6.2 Market Share Comparison, By Region
          4.3.6.3 Y-o-Y growth Comparison, By Region
    4.3.7 Colorectal Cancer Market Size and Forecast, 2012-2026
          4.3.7.1 Revenue (US$ Mn) Comparison, By Region
          4.3.7.2 Market Share Comparison, By Region
          4.3.7.3 Y-o-Y growth Comparison, By Region
    4.3.8 Other Cancers Market Size and Forecast, 2012-2026
          4.3.8.1 Revenue (US$ Mn) Comparison, By Region
          4.3.8.2 Market Share Comparison, By Region
          4.3.8.3 Y-o-Y growth Comparison, By Region

Chapter 5 North America Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026
5.1 North America Market Outlook
5.2 North America Pharmaceutical Industry Outlook
5.3 Revenue (US$ Mn) Comparison, By Country
5.4 Revenue (US$ Mn) Comparison, By Drug Class
5.5 Revenue (US$ Mn) Comparison, By Distribution Channel
5.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 6 Latin America Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026
6.1 Latin America Market Outlook
6.2 Latin America Pharmaceutical Industry Outlook
6.3 Revenue (US$ Mn) Comparison, By Country
6.4 Revenue (US$ Mn) Comparison, By Drug Class
6.5 Revenue (US$ Mn) Comparison, By Distribution Channel
6.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 7 Europe Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026
7.1 Europe Market Outlook
7.2 Europe Pharmaceutical Industry Outlook
7.3 Revenue (US$ Mn) Comparison, By Country
7.4 Revenue (US$ Mn) Comparison, By Drug Class
7.5 Revenue (US$ Mn) Comparison, By Distribution Channel
7.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 8 Japan Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026
8.1 Japan Market Outlook
8.2 Japan Pharmaceutical Industry Outlook
8.3 Revenue (US$ Mn) Comparison, By Country
8.4 Revenue (US$ Mn) Comparison, By Drug Class
8.5 Revenue (US$ Mn) Comparison, By Distribution Channel
8.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 9 APEJ Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026
9.1 APEJ Market Outlook
9.2 APEJ Pharmaceutical Industry Outlook
9.3 Revenue (US$ Mn) Comparison, By Country
9.4 Revenue (US$ Mn) Comparison, By Drug Class
9.5 Revenue (US$ Mn) Comparison, By Distribution Channel
9.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 10 MEA Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026
10.1 MEA Market Outlook
10.2 MEA Pharmaceutical Industry Outlook
10.3 Revenue (US$ Mn) Comparison, By Country
10.4 Revenue (US$ Mn) Comparison, By Drug Class
10.5 Revenue (US$ Mn) Comparison, By Distribution Channel
10.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 11 Global Immune Checkpoint Inhibitors Market Company Share, Competition Landscape and Company Profiles
11.1 Global Immune Checkpoint Inhibitors Market - Company Share Analysis
11.2 Global Immune Checkpoint Inhibitors Market - Competitive Landscape
11.3 Global Immune Checkpoint Inhibitors Market - Company Profile
    11.3.1 AstraZeneca Plc.
          11.3.1.1 Company Overview
          11.3.1.2 Product Overview
          11.3.1.3 Key Financials
          11.3.1.4 Key Developments
          11.3.1.5 SWOT Analysis
    11.3.2 Bristol-Myers Squibb Co.
          11.3.2.1 Company Overview
          11.3.2.2 Product Overview
          11.3.2.3 Key Financials
          11.3.2.4 Key Developments
          11.3.2.5 SWOT Analysis
    11.3.3 Celldex Therapeutics Inc.
          11.3.3.1 Company Overview
          11.3.3.2 Product Overview
          11.3.3.3 Key Financials
          11.3.3.4 Key Developments
          11.3.3.5 SWOT Analysis
    11.3.4 Roche Holding AG
          11.3.4.1 Company Overview
          11.3.4.2 Product Overview
          11.3.4.3 Key Financials
          11.3.4.4 Key Developments
          11.3.4.5 SWOT Analysis
    11.3.5 Incyte Corporation
          11.3.5.1 Company Overview
          11.3.5.2 Product Overview
          11.3.5.3 Key Financials
          11.3.5.4 Key Developments
    11.3.6 Merck & Co., Inc.
          11.3.6.1 Company Overview
          11.3.6.2 Product Overview
          11.3.6.3 Key Financials
          11.3.6.4 Key Developments
          11.3.6.5 SWOT Analysis
    11.3.7 Merck KGaA
          11.3.7.1 Company Overview
          11.3.7.2 Product Overview
          11.3.7.3 Key Financials
          11.3.7.4 Key Developments
          11.3.7.5 SWOT Analysis
    11.3.8 Pfizer Inc.
          11.3.8.1 Company Overview
          11.3.8.2 Product Overview
          11.3.8.3 Key Financials
          11.3.8.4 Key Developments
          11.3.8.5 SWOT Analysis
    11.3.9 Sanofi
          11.3.9.1 Company Overview
          11.3.9.2 Product Overview
          11.3.9.3 Key Financials
          11.3.9.4 Key Developments
          11.3.9.5 SWOT Analysis
    11.3.10 Novartis AG
          11.3.10.1 Company Overview
          11.3.10.2 Product Overview
          11.3.10.3 Key Financials
          11.3.10.4 Key Developments
          11.3.10.5 SWOT Analysis

Chapter 12 PMR Research Methodology

Chapter 13 Disclaimer


List of Tables

TABLE 1 Global Immune Checkpoint Inhibitors Market Value (US$ Mn), 2012-2017
TABLE 2 Global Immune Checkpoint Inhibitors Market Value (US$ Mn), 2018-2026
TABLE 3 Global Immune Checkpoint Inhibitors Market Value (US$ Mn) and Y-o-Y, 2017-2026
TABLE 4 Global PD-1 Segment Value (US$ Mn), By Region 2012-2017
TABLE 5 Global PD-1 Segment Value (US$ Mn), By Region 2018-2026
TABLE 6 Global PD-1 Segment Market Share, By Region 2012-2017
TABLE 7 Global PD-1 Segment Market Share, By Region 2018-2026
TABLE 8 Global PD-1 Segment Y-o-Y, By Region 2017-2026
TABLE 9 Global PD-L1 Segment Value (US$ Mn), By Region 2012-2017
TABLE 10 Global PD-L1 Segment Value (US$ Mn), By Region 2018-2026
TABLE 11 Global PD-L1 Segment Market Share, By Region 2012-2017
TABLE 12 Global PD-L1 Segment Market Share, By Region 2018-2026
TABLE 13 Global PD-L1 Segment Y-o-Y, By Region 2017-2026
TABLE 14 Global CTLA-4 Segment Value (US$ Mn), By Region 2012-2017
TABLE 15 Global CTLA-4 Segment Value (US$ Mn), By Region 2018-2026
TABLE 16 Global CTLA-4 Segment Market Share, By Region 2012-2017
TABLE 17 Global CTLA-4 Segment Market Share, By Region 2018-2026
TABLE 18 Global CTLA-4 Segment Y-o-Y, By Region 2017-2026
TABLE 19 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 20 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 21 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
TABLE 22 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
TABLE 23 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 24 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 25 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 26 Global Retail Pharmacies Segment Market Share, By Region 2012-2017
TABLE 27 Global Retail Pharmacies Segment Market Share, By Region 2018-2026
TABLE 28 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 29 Global Specialty Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 30 Global Specialty Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 31 Global Specialty Pharmacies Segment Market Share, By Region 2012-2017
TABLE 32 Global Specialty Pharmacies Segment Market Share, By Region 2018-2026
TABLE 33 Global Specialty Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 34 Global Melanoma Segment Value (US$ Mn), By Region 2012-2017
TABLE 35 Global Melanoma Segment Value (US$ Mn), By Region 2018-2026
TABLE 36 Global Melanoma Segment Market Share, By Region 2012-2017
TABLE 37 Global Melanoma Segment Market Share, By Region 2018-2026
TABLE 38 Global Melanoma Segment Y-o-Y, By Region 2017-2026
TABLE 39 Global Lung Cancer Segment Value (US$ Mn), By Region 2012-2017
TABLE 40 Global Lung Cancer Segment Value (US$ Mn), By Region 2018-2026
TABLE 41 Global Lung Cancer Segment Market Share, By Region 2012-2017
TABLE 42 Global Lung Cancer Segment Market Share, By Region 2018-2026
TABLE 43 Global Lung Cancer Segment Y-o-Y, By Region 2017-2026
TABLE 44 Global Blood Cancers Segment Value (US$ Mn), By Region 2012-2017
TABLE 45 Global Blood Cancers Segment Value (US$ Mn), By Region 2018-2026
TABLE 46 Global Blood Cancers Segment Market Share, By Region 2012-2017
TABLE 47 Global Blood Cancers Segment Market Share, By Region 2018-2026
TABLE 48 Global Blood Cancers Segment Y-o-Y, By Region 2017-2026
TABLE 49 Global Renal Cell Carcinoma Segment Value (US$ Mn), By Region 2012-2017
TABLE 50 Global Renal Cell Carcinoma Segment Value (US$ Mn), By Region 2018-2026
TABLE 51 Global Renal Cell Carcinoma Segment Market Share, By Region 2012-2017
TABLE 52 Global Renal Cell Carcinoma Segment Market Share, By Region 2018-2026
TABLE 53 Global Renal Cell Carcinoma Segment Y-o-Y, By Region 2017-2026
TABLE 54 Global Squamous Cell Carcinoma Segment Value (US$ Mn), By Region 2012-2017
TABLE 55 Global Squamous Cell Carcinoma Segment Value (US$ Mn), By Region 2018-2026
TABLE 56 Global Squamous Cell Carcinoma Segment Market Share, By Region 2012-2017
TABLE 57 Global Squamous Cell Carcinoma Segment Market Share, By Region 2018-2026
TABLE 58 Global Squamous Cell Carcinoma Segment Y-o-Y, By Region 2017-2026
TABLE 59 Global Urothelial Carcinoma Segment Value (US$ Mn), By Region 2012-2017
TABLE 60 Global Urothelial Carcinoma Segment Value (US$ Mn), By Region 2018-2026
TABLE 61 Global Urothelial Carcinoma Segment Market Share, By Region 2012-2017
TABLE 62 Global Urothelial Carcinoma Segment Market Share, By Region 2018-2026
TABLE 63 Global Urothelial Carcinoma Segment Y-o-Y, By Region 2017-2026
TABLE 64 Global Colorectal Cancer Segment Value (US$ Mn), By Region 2012-2017
TABLE 65 Global Colorectal Cancer Segment Value (US$ Mn), By Region 2018-2026
TABLE 66 Global Colorectal Cancer Segment Market Share, By Region 2012-2017
TABLE 67 Global Colorectal Cancer Segment Market Share, By Region 2018-2026
TABLE 68 Global Colorectal Cancer Segment Y-o-Y, By Region 2017-2026
TABLE 69 Global Other Cancers Segment Value (US$ Mn), By Region 2012-2017
TABLE 70 Global Other Cancers Segment Value (US$ Mn), By Region 2018-2026
TABLE 71 Global Other Cancers Segment Market Share, By Region 2012-2017
TABLE 72 Global Other Cancers Segment Market Share, By Region 2018-2026
TABLE 73 Global Other Cancers Segment Y-o-Y, By Region 2017-2026
TABLE 74 North America Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 75 North America Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 76 North America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 77 North America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 78 North America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 79 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
TABLE 80 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
TABLE 81 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 82 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 83 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 84 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 85 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
TABLE 86 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026
TABLE 87 Latin America Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 88 Latin America Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 89 Latin America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 90 Latin America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 91 Latin America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 92 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
TABLE 93 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
TABLE 94 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 95 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 96 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 97 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 98 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
TABLE 99 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026
TABLE 100 Europe Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 101 Europe Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 102 Europe Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 103 Europe Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 104 Europe Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 105 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
TABLE 106 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
TABLE 107 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 108 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 109 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 110 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 111 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
TABLE 112 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026
TABLE 113 Japan Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 114 Japan Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 115 Japan Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 116 Japan Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 117 Japan Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 118 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
TABLE 119 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
TABLE 120 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 121 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 122 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 123 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 124 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
TABLE 125 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026
TABLE 126 APEJ Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 127 APEJ Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 128 APEJ Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 129 APEJ Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 130 APEJ Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 131 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
TABLE 132 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
TABLE 133 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 134 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 135 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 136 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 137 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
TABLE 138 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026
TABLE 139 MEA Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 140 MEA Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 141 MEA Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 142 MEA Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 143 MEA Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 144 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
TABLE 145 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
TABLE 146 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
TABLE 147 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
TABLE 148 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 149 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 150 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
TABLE 151 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026


List of Figures

FIG. 1 Global Immune Checkpoint Inhibitors Market Value (US$ Mn), 2012-2017
FIG. 2 Global Immune Checkpoint Inhibitors Market Value (US$ Mn) Forecast, 2018-2026
FIG. 3 Global Immune Checkpoint Inhibitors Market Value (US$ Mn) and Y-o-Y, 2017-2026
FIG. 4 Global PD-1 Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 5 Global PD-1 Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 6 Global PD-1 Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 7 Global PD-L1 Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 8 Global PD-L1 Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 9 Global PD-L1 Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 10 Global CTLA-4 Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 11 Global CTLA-4 Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 12 Global CTLA-4 Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 13 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 14 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 15 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 16 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 17 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 18 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 19 Global Specialty Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 20 Global Specialty Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 21 Global Specialty Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 22 Global Melanoma Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 23 Global Melanoma Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 24 Global Melanoma Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 25 Global Lung Cancer Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 26 Global Lung Cancer Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 27 Global Lung Cancer Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 28 Global Blood Cancers Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 29 Global Blood Cancers Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 30 Global Blood Cancers Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 31 Global Renal Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 32 Global Renal Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 33 Global Renal Cell Carcinoma Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 34 Global Squamous Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 35 Global Squamous Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 36 Global Squamous Cell Carcinoma Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 37 Global Urothelial Carcinoma Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 38 Global Urothelial Carcinoma Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 39 Global Urothelial Carcinoma Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 40 Global Colorectal Cancer Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 41 Global Colorectal Cancer Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 42 Global Colorectal Cancer Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 43 Global Other Cancers Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 44 Global Other Cancers Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 45 Global Other Cancers Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 46 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
FIG. 47 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
FIG. 48 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 49 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 50 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 51 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 52 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
FIG. 53 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026
FIG. 54 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
FIG. 55 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
FIG. 56 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 57 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 58 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 59 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 60 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
FIG. 61 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026
FIG. 62 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
FIG. 63 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
FIG. 64 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 65 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 66 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 67 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 68 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
FIG. 69 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026
FIG. 70 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
FIG. 71 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
FIG. 72 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 73 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 74 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
FIG. 75 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 76 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
FIG. 77 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026
FIG. 78 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
FIG. 79 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
FIG. 80 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 81 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 82 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 83 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 84 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
FIG. 85 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026
FIG. 86 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017
FIG. 87 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026
FIG. 88 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017
FIG. 89 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026
FIG. 90 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 91 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 92 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017
FIG. 93 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-202